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https://doi.org/10.1016/j.stemcr.2018.10.013SUMMARYSpecifying the primitive streak (PS) guides stem cell differentiation in vitro; however, much remains to be learned about the tran-
scription networks that direct anterior and posterior PS cells (APS and PPS, respectively) to differentiate to distinct mesendodermal
subpopulations. Here, we show that APS genes are predominantly induced in YAP1/ human embryonic stem cells (hESCs) in
response to ACTIVIN. This finding establishes the Hippo effector YAP1 as a master regulator of PS specification, functioning to
repress ACTIVIN-regulated APS genes in hESCs. Moreover, transient exposure of wild-type hESCs to dasatinib, a potent C-SRC/
YAP1 inhibitor, enables differentiation to APS-derived endoderm and cardiac mesoderm in response to ACTIVIN. Importantly, these
cells can differentiate efficiently to normal beating cardiomyocytes without the cytoskeletal defect seen in YAP1/ hESC-derived
cardiomyocytes. Overall, we uncovered an induction mechanism to generate APS cells using a cocktail of ACTIVIN and YAP1i mol-
ecules that holds practical implications for hESC and induced pluripotent stem cell differentiation into distinct mesendodermal
lineages.INTRODUCTION
During embryonic development, gastrulation is marked
by the formation of the primitive streak (PS). Within
the PS, cells are directed to specific fates based on their
spatiotemporal position. Thus, cells from the anterior
part of the PS (APS) form the endoderm and cardiac
mesoderm, whereas posterior PS (PPS) derivatives are
destined to populate the extraembryonic and somitic
mesoderm (Murry and Keller, 2008; Wang and Chen,
2016). As a consequence, the anterior and posterior
regions of the PS have unique differentiation potentials
and depend on different transcription networks to guide
their exit from pluripotency along the anterior-posterior
PS axis.
The induction of the PS in mouse embryos or cultured
human epiblast cells is directed by ACTIVIN/NODAL and
WNT signaling (Brennan et al., 2001; Gadue et al., 2006;
Liu et al., 1999; Martyn et al., 2018; Sumi et al., 2008). In
epiblast cells, WNT/b-CATENIN and ACTIVIN/SMAD2,3
cooperate to transcribe pan-PS lineage genes, such as
MIXL1 and EOMES. Relatively high levels of ACTIVIN
direct APS differentiation toward endoderm (SOX17+),
both in vitro and in vivo, while inhibiting posterior fates
through the repression of PPS genes, such as CDX2
(D’Amour et al., 2005; Gritsman et al., 2000; Mendjan
et al., 2014). In turn, posterior gene markers, such as
CDX2, MSGN1, and TBX6 are targets of WNT/b-CATENIN
signaling. The expression of these latter genes correlates
with WNT levels, and consequently stronger WNT signalsStem Cell Reports
This is an open access article under the Ccontribute to the PPS fate (Amin et al., 2016; Wittler
et al., 2007; Yamaguchi et al., 1999).
PS patterning also depends on other factors. For example,
the DNA demethylase TET activates Lefty to downregulate
NODAL levels along the streak in mouse embryos (Dai
et al., 2016), whereas the transcription factor ZFP281 re-
presses TET expression to activate genes important for
NODAL signaling, such as Nodal and Foxh1 (Fidalgo et al.,
2016; Huang et al., 2017). In addition, the tumor suppres-
sor P53 regulates PS differentiation by repressing Wnt3
expression in mouse embryonic stem cells (ESCs) (Wang
et al., 2017). Pluripotency factors are also key players of
PS specification. For instance, early downregulation of
SOX2 is required to exit pluripotency, whereas OCT4 regu-
lates SOX17 expression, and NANOG cooperates with
SMAD2,3 to induce mid-anterior and APS fates via repres-
sion of CDX2 (Aksoy et al., 2013; Mendjan et al., 2014;
Rao et al., 2016). These findings suggest that factors
contributing to fine-tune WNT and NODAL signaling are
key to pattern the PS.
Extending these findings, we recently discovered that the
Hippo effector YAP1 (Fu et al., 2017) strongly regulates the
activity of WNT and ACTIVIN signaling in human embry-
onic stem cells (hESCs) and induced pluripotent stem cells
(iPSCs) (Estarasetal., 2015,2017).Bindingof theYAP1:TEAD
complex toWNT3andNODAL enhancers inhESCs represses
transcription of these ligands and block expression ofWNT-
ACTIVIN co-induced pan-PS genes. Importantly, long-term
analysis of YAP1/ hESCs revealed that these cells differen-
tiate selectively along the cardiac lineage in response toj Vol. 11 j 1357–1364 j December 11, 2018 j ª 2018 The Authors. 1357
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. YAP1 Depletion in hESCs Induces APS Fate in Response to ACTIVIN
(A) A diagram illustrating the potential role of YAP1 in specifying PS fate.
(B) Left: immunostaining of YAP1 and SOX2 in H1 hESCs treated with ACTIVIN or ACTIVIN + dasatinib (YAP1i) for 24 hr. Right: CTGF mRNA
abundance (qRT-PCR) in H1 hESCs treated with dasatinib for 24 hr. The final concentration of dasatinib varied from 0, 5, and 10 to 20 nM.
(C) mRNA abundance of tested pan-PS genes in WT and YAP1/ H1 hESCs at 24 hr following the indicated treatments.
(D) An RNA-seq heatmap for two biological independent replicates of WT or YAP1/ H1 hESCs, untreated or treated with ACTIVIN for 24 hr.
(E) mRNA abundance of APS (LHX1 and SOX17) and PPS (MSGN1 and CDX2) genes. The final concentration of dasatinib (YAP1i) was 10 nM.
nR 3 biological independent experiments, mean ± SD.
Statistical significance of difference by paired two-tailed t test; *p < 0.05; ***p < 0.001. Non-significant differences are not marked.ACTIVIN. These findings suggest that YAP1 regulates genes
important for differentiation toward the APS fate, which is
the precursor of cardiac mesoderm.
To further elaborate the role of YAP1 in PS differentiation,
we used both CRISPR-engineered YAP1 knockout hESCs
and an inhibitor to temporally disrupt YAP1 activity in
hESCs. We show that YAP1/ hESCs specify into APS pro-
genitors (LHX1+/SOX17+/CDX2/TBX6) in response to
ACTIVIN. The YAP/-derived APS cells further progress
into cardiac mesoderm and endoderm. Importantly, we
demonstrate that transient inactivation of YAP1 in hESCs
using the dasatinib C-SRC/YAP1 inhibitor efficiently gave
rise to functional cardiomyocytes using a one-step strategy.
These findings demonstrate that YAP1 is a key regulator of
APS specification, and provide a coherent strategy to guide
stem cell differentiation along the endoderm and cardiac
lineages.1358 Stem Cell Reports j Vol. 11 j 1357–1364 j December 11, 2018RESULTS
Transient Inhibition of YAP1 Induces hESC
Differentiation along the Anterior PS Cell Fate
We have shown that YAP1/ hESCs progress toward car-
diac lineage in response to ACTIVIN (Estaras et al., 2017).
The cardiac lineage derives from the mid-anterior part of
the PS, and therefore we hypothesize that inhibition of
YAP1 activity in hESCs favors differentiation to anterior-
like progenitors in response to ACTIVIN. Thus, we aimed
to explore whether transient inactivation of YAP1 in hESCs
affects the specification of PS progenitors (Figure 1A). To
begin, we treated wild-type (WT) hESCs with dasatinib, a
small-molecule C-SRC kinase inhibitor shown to affect
the actin cytoskeleton and compromise the stability of
YAP1 (Zanconato et al., 2016). Figure 1B shows that 24 hr
dasatinib (YAP1i) treatment in hESCs effectively decreased
YAP1 protein levels along with a dose-dependent reduction
of theYAP1 target gene,CTGF.Wenext testedwhether tran-
sient exposure to YAP1i is sufficient to induce widely ex-
pressed pan-PS genes. As shown in Figure 1C, the combined
ACTIVIN +YAP1i treatment inWTcells induced expression
of MIXL1, EOMES, and T genes to levels comparable with
those seen in YAP1/ hESCs treated with ACTIVIN. These
results were consistent among two different hESCs lines
(H1 and H9), also the EC11 iPSC line (Figure S1).
hESCs can differentiate into anterior- and posterior-like
PS cells, which are partially committed precursors that
give rise to distinct mesoderm and endoderm tissues. To
further investigate the identity of the YAP1-depleted PS
cells, we examined their transcriptome by RNA sequencing
(RNA-seq) (Estaras et al., 2017). Surprisingly, we found that
ACTIVIN-treated YAP1/ hESCs express high levels of APS
markers, such as SOX17, LHX1, and HAND1, but low levels
of PPS markers (MSGN1, CDX2, and HOXA1) compared
with ACTIVIN-treated WT hESCs. Moreover, we found
that hESCs treated with ACTIVIN + YAP1i also express
high levels of APS, but not PPS markers (Figure 1E). We
conclude that ACTIVIN treatment in YAP1-null human
pluripotent stem cells (hPSCs) induces APS fate. Overall,
these data show that YAP1 regulates the A-P specification
of PS, and provides a specific approach to generate APS cells
from hPSCs in vitro, through a brief exposure to ACTIVIN
and dasatinib (YAP1i).
YAP1Does Not Regulate Differentiation to Posterior PS
Cell Fate
In hESCs, a strong WNT/b-CATENIN signal promotes the
induction of PPS fate. In agreement with this finding,
RNA-seq analysis of WNT signaling in WT hESCs treated
with a GSK3 inhibitor (GSK3i) (factor XV), revealed strong
expression of pan-PS and PPS genes, including MSGN1,
EVX1, and HOXA1, but no significant induction of the
APS transcriptome (Figure 2A). Interestingly, loss of YAP1
did not significantly affect the induction of the PPS genes
by GSK3i. Neither inhibition nor loss of YAP1 altered the
induction of PPS genes in response to ACTIVIN (Figures 2
and S2). In contrast, YAP1 inactivation potentiated the
expression of some APS genes under GSK3i treatments,
including HHEX and LHX1 (Figures 2A–2C), but the effect
was less dramatic relative to that seen in ACTIVIN-treated
cells. Taken together, these results indicate that YAP1 selec-
tively represses the APS genes in hESCs by counteracting
ACTIVIN signaling.
ACTIVIN + Dasatinib (YAP1i)-Derived PS Cells Can
Differentiate along the Endoderm and Cardiac Cell
Lineages
These data show that exposure of hESCs to a combina-
tion of ACTIVIN with dasatinib (YAP1i) leads to stronginduction of APS genes, whereas WNT/GSK3i induces
the PPS genes. These divergent roles of ACTIVIN and
WNT in specifying PS cell fates prompted us to assess
possible differences in their developmental potential.
We first evaluated the ability of the ACTIVIN + YAP1i-
induced PS cells to differentiate toward two anterior de-
rivatives, endoderm and the cardiac lineages. Following
24 hr incubation with ACTIVIN and YAP1i, the medium
was replaced and the cells were analyzed following a
total of 5 days in culture. As shown in Figures 3A and
3B, the ACTIVIN + YAP1i-induced PS cells expressed
high levels of the cardiac precursor marker, NKX2.5
(Paige et al., 2015), indicating that these cells acquired
a cardiac lineage without any additional treatment (con-
dition C). To test whether the ACTIVIN + YAP1i-derived
PS cells can differentiate into endoderm, the cells were
exposed to a prolonged ACTIVIN signaling (days 2–5)
(Mallanna and Duncan, 2013). Importantly, the ACTI-
VIN + YAP1i-exposed PS cells express high levels of
SOX17, strongly suggesting that these precursors had
differentiated to endoderm cells (Figures 3A and 3B, con-
dition D).
Finally, we examined the capacity of the ACTIVIN +
YAP1i-treated cells to differentiate into posterior deriva-
tives by analyzing the expression of the paraxial gene
MEOX1 (Mankoo et al., 2003) at day 5 following the initial
treatment. Interestingly, we found thatMEOX1 expression
remained low in the ACTIVIN + YAP1i-treated cells (Fig-
ure 3B, condition C) in contrast to the high expression in
the GSK3i-treated cells (Figure 3B, condition B). In accor-
dance with their posterior nature, the GSK3i-induced PS
cells failed to differentiate into anterior cardiac lineages
or endoderm (Figure 3B, condition A).Overall, we conclude
that unlike GSK3i, a treatment combining ACTIVIN and
YAP1i is effective to generate PS precursors with a differen-
tiation capacity toward anterior and mid-anterior
derivatives.
PS Progenitors Can Be Reprogrammed
We have demonstrated that GSK3i-induced PPS cells are
prone to acquire a paraxial fate. Therefore, it seems
contrary to employ WNT ligands or GSK3i as the most
common practice for inducing cardiac differentiation.
Noteworthy, the GSK3i-dependent cardiomyocyte differ-
entiation requires an additional step at 3 days that is
designed to block further WNT signaling (referred to as
GiWi protocol in Lian et al., 2013; Loh et al., 2016).
It is shown that the addition of a WNT inhibitor is
necessary to cease the expression of key cardiac inhibitors
such as CDX2 andMSX1, allowing the cells to adopt a car-
diac fate (Rao et al., 2016) (Figure S3). We hypothesize
that the WNT inhibitor may also serve to suppress the
expression of paraxial markers, and therefore redirectStem Cell Reports j Vol. 11 j 1357–1364 j December 11, 2018 1359
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Figure 2. Differentiation to PPS Fate Is Independent of YAP1
(A) An RNA-seq heatmap of WT or YAP1/ H1 hESCs, untreated, or treated with either ACTIVIN or GSK3i for 24 hr, as indicated
(two biological independent replicates).
(B) Representative loci of APS and PPS genes from RNA-seq.
(C) A bubble chart to summarize the dependency of pan-PS, APS, and PPS induction on YAP1 activity. Bubble sizes represent the log2 scale
average gene expression. Bubble colors represent YAP1 logFC, defined as the average logFC of YAP1/ over WT expression under each
treatment (GSKi or ACTIVIN).
(D) mRNA abundance of LHX1 and MSGN1 in WT and YAP1/ H1 hESCs treated as indicated, for 24 hr. The final concentration of dasatinib
(YAP1i) was 10 nM. n = 3 biological independent experiments, mean ± SD.
*p < 0.05; ***p < 0.001.the posterior PS cells toward cardiac mesoderm. To test
this possibility, we analyzed the expression of paraxial
and cardiac genes in the presence or absence of WNT
inhibitor, which was added 2 days following the GSK3i
treatment (Figure 3A, conditions A and B). As predicted,
Figure 3B (condition B) shows that the exposure to a
WNT inhibitor strongly favors the induction of the car-
diac lineage marker NKX2.5 in GSK3i-treated cells. More
importantly, the WNT inhibitor also impairs the induc-
tion of the paraxial gene,MEOX1. Consequently, blocking
of WNT signaling reprograms the PPS precursors from a
paraxial to a cardiac cell fate (Figure 3B, conditions
A and B). These findings demonstrate that APS and PPS
cells are not fully committed precursors, but rather can
be redirected to alternate fates in response to appropriate
developmental cues.1360 Stem Cell Reports j Vol. 11 j 1357–1364 j December 11, 2018ACTIVIN + YAP1i Treatment Provides an Alternative
Strategy for Cardiac Induction
Thus far, these data strongly indicate that combined treat-
ment of ACTIVIN and YAP1i during the first 24 hr of differ-
entiation in WT hESCs and hiPSCs is sufficient to generate
APScells that efficientlydifferentiate intocardiacmesoderm
(NKX2.5+/GATA4+/CDX2) (Figures 3 and S3). Thus, we
reasoned that transient ACTIVIN + YAP1i exposure might
provide an alternative strategy to generate cardiomyocytes
inWT hESCs (Figure 4A). To test this possibility, we investi-
gated the expression of cardiac markers following a full
14 days of differentiation. Indeed, ACTIVIN + YAP1i-treated
hESCs express high levels of the CTNT, MLC2-A, and
NKX2.5 cardiac markers (Figure 4B). Importantly, fluores-
cence-activated cell sorting analysis revealed that approxi-
mately 70% of the ACTIVIN + YAP1i-treated PS cells were
A C
B
Figure 3. ACTIVIN + Dasatinib (YAP1i)-Derived PS Cells Differentiate into Endoderm and Cardiac Lineages
(A) The diagram illustrates the different procedures that were tested for hESC differentiation.
(B) mRNA abundance of MEOX1, NKX2.5, and SOX17 on day 5 from the initial treatments in H1 hESCs, as indicated in diagram. n = 3
biological independent experiments, mean ± SD. *p < 0.05; ***p < 0.001.
(C) The diagram illustrates the various signaling cues that direct PS fate specification to mesendodermal lineages.CTNT positive, which is similar to the cardiomyocyte yield
from the GiWi protocol (Lian et al., 2013) (Figures 4C and
S4B). In addition, active beating cardiomyocytes derived
from ACTIVIN + YAP1i treatment were observed in culture
from day 8 onward (Video S1). As shown in the Venn dia-
gram of Figure 4D, the transcriptome of the ACTIVIN +
YAP1i-derived cardiomyocytes shows extensive overlap
with that of cardiomyocytes derived using the GiWi proto-
col, and the heatmap further establishes that key cardiac
marker genes are strongly expressed in cardiac cells derived
from both protocols.
We have recently reported that YAP1/-derived cardio-
myocytes are viable; however, the organization of the
actin cytoskeleton is significantly compromised (Estaras
et al., 2017), as shown by immunostaining with CTNT
(Figure 4E). Importantly, analysis of the ACTIVIN +
YAP1i-derived cardiomyocytes revealed an intact actin
cytoskeleton that resembles cardiomyocytes obtained
using the GiWi strategy. We conclude that the one-step
strategy (ACTIVIN + dasatinib [YAP1i]) is an effective
approach for the generation of functional cardiomyocytes.In summary, this work shows that ACTIVIN + YAP1i co-
treatment in hESCs provides a robust method to generate
APS cells that effectively differentiate into endoderm and
cardiac lineages (Figure 4F).DISCUSSION
Transcription factors involved inprimitive streakpatterning
play an essential role in early organogenesis and stem cell
differentiation. Here, we show that YAP1 is a key regulator
of PS cell specification through its ability to selectively
repress the expression of genes for APS fate. We find that
YAP1 represses ACTIVIN target genes, including SOX17,
without affecting the expression of PPS genes. As a result,
the loss of YAP1 in hESCs exposed to ACTIVIN enables effi-
cient differentiation toward the APS cell fate.We previously
showed that YAP1 inhibits hESC differentiation to cardiac
mesoderm (Estaras et al., 2017). Here, we extend these find-
ings by showing that YAP1 inhibits APS gene expression to
restrain the cardiac fate. Moreover, we further discoveredStem Cell Reports j Vol. 11 j 1357–1364 j December 11, 2018 1361
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Figure 4. ACTIVIN + Dasatinib (YAP1i) Treatment Is an Alternative Strategy for Cardiomyocyte Differentiation
(A) Steps of the GiWi and one-step protocols for cardiomyocyte differentiation.
(B) Immunoblots of MLC-2A, CTNT, and NKX2.5 expression on day 14 of H1 hESC treatment.
(C) Fluorescence-activated cell sorting analysis of CTNT+ cells on day 14 of treatments. n = 3 biological independent experiments,
mean ± SD. ***p < 0.001.
(D) Left: a Venn diagram summarized the RNA-seq data showing upregulated genes in cardiomyocytes derived from GiWi or one-step
protocols. Right: a heatmap of the top 50 upregulated cardiac genes in H1 hESCs and cardiomyocytes generated from the GiWi or one-step
protocols, respectively. Two biological independent experiments of hESCs and GiWi-derived cardiomyocytes (CMs), and three biological
independent experiments of YAP1i-derived CMs.
(E) Immunostaining of CTNT in cardiomyocytes derived from WT or YAP1/ H1 hESCs following the GiWi or one-step protocols.
(F) The schematic depicts the strategy of APS specification for cardiac mesoderm and endoderm differentiation.that APS cells generated from hESCs treated with ACTIVIN
and the YAP1-inhibitor dasatinib can further differentiate
to endoderm cells capable of further development to lung,
liver, or pancreatic b cells.
How does YAP1 repress APS fate in hESCs? Several lines
of evidence suggest that ACTIVIN acts in a dose-depen-
dent manner to induce APS cell fate. In mouse models
and ESCs, high ACTIVIN levels induce the APS markers
Sox17, Foxa2, and Cer1, and repress the PPS marker Cdx2
(Brennan et al., 2001; Estaras et al., 2017; Mendjan
et al., 2014). Our observation that YAP1 represses NODAL
in hESCs raises the possibility that elevated SMAD2,3
signaling in YAP1/ cells may contribute to this pheno-
type (Estaras et al., 2017). Nevertheless, high ACTIVIN/
NODAL signaling is not sufficient to induce an APS fate1362 Stem Cell Reports j Vol. 11 j 1357–1364 j December 11, 2018in WT hESCs, indicating the existence of other key YAP1
targets. Consistent with this idea, we find that YAP1 coun-
teracts the ability of ACTIVIN/SMAD2,3 to repress the
WNT3 gene in hESCs. In the absence of YAP1, SMAD2,3
activate endogenous WNT3 and nuclear b-CATENIN
to initiate the PS program. Consequently, exposure of
hESCs to WNT or GSK3i can overcome the ability of
YAP1 to repress pan-PS genes in response to ACTIVIN.
However, GSK3i treatment or WNT signaling does not
bypass the need for YAP1 to repress the APS genes. Conse-
quently, the APS gene program is induced in response to
ACTIVIN only in cells that lack YAP1 activity. What are
the key YAP1 targets? RNA-seq analysis of YAP1/ hESCs
exposed to ACTIVIN revealed SOX17, a master regulator of
endoderm and cardiac mesoderm specification (Liu et al.,
2007; Viotti et al., 2014). In addition to pan-PS genes, we
speculate that YAP1 also counteracts SMAD2,3-dependent
transcription on APS genes, such as SOX17, to regulate PS
specification. Further studies are needed to examine
whether YAP1 and SMAD2,3 bind differentially to APS
and PPS genes. Taken together, we conclude that YAP1
depletion in hESCs unlocks the ability of ACTIVIN to
induce differentiation by activating endogenous WNT3
signaling and allowing SMAD2,3 to induce pan-PS and
APS genes, such as SOX17.
hPSC differentiation is an excellent model to identify
new regulators and mechanisms of cell differentiation in
embryos (Ang et al., 2016). Accordingly, the phenotype
of YAP1/ embryos recapitulates the misregulation of
the PS gene expression that we observe in YAP1/ hESCs.
YAP1/ embryos die soon after the onset of gastrulation,
indicating a crucial role of YAP1 in the specification of three
germ layers in vivo. Analyses of embryos at the peri-gastru-
lation stage reveals that the PS in YAP1/ embryos appears
shorter and broader than in WT embryos (Morin-Kensicki
et al., 2006). We speculate that the anterior-posterior axis
defects in YAP1/ embryos reflect the inability of YAP1
to repress APS genes. These findings suggest that the PS ab-
normality in YAP1/ embryosmight include an expanded
APS domain (SOX17+/CDX2) with a curtailed or absent
PPS domain (CDX2+), similar to YAP1/hESCs that prefer-
entially induce the APS but not PPS program. In addition,
YAP1 expression in developing embryos is lower within
the region of the PS destined to become endoderm later
in development. Thus, low levels of YAP1 likely favor the
in vivo specification of APS precursors, as we observed in
hESCs. Altogether, these findings suggest that distinct
levels of YAP1 along the anterior-posterior axis could serve
as a sensor to enable cells to exit pluripotency and adopt
specific PS fates.
Lastly, we extend our findings to an alternative strategy
for directing hESC and iPSC differentiation using a com-
bined ACTIVIN and dasatinib (YAP1i) treatment. We
show that a transient exposure of WT hESCs to ACTIVIN
and dasatinib is sufficient to generate beating cardio-
myocytes. Of note, we find that including ACTIVIN and
dasatinib in the stem cell medium, without additional
supplements, is sufficient to initiate hESC specification
along the APS lineage. This simple procedure illuminates
the critical control of ACTIVIN signaling and YAP1 activ-
ity in APS induction. Most importantly, the transient in-
hibition of YAP1 eliminates the severe cytoskeletal defects
observed in YAP1/ hESC-derived cardiomyocytes, and
bypasses the need for cell engineering. Consequently,
the use of ACTIVIN and dasatinib to induce hESCs and
iPSCs to undergo APS differentiation along the cardio-
myocyte lineage may provide a useful step toward the
therapeutic goals of regenerative medicine.EXPERIMENTAL PROCEDURES
ACTIVIN One-Step Cardiomyocyte Differentiation
WT hESC cultures were disaggregated into single cells using Accu-
tase. Cells were seeded at 200,000 cells/well in Matrigel-coated
24-well plates and grown until reaching 80% confluence. At day
0, hESCs were simultaneously treated with dasatinib (10 nM,
Sigma) and ACTIVIN (100 ng/mL) in the mTeSR1 medium for
24 hr. Then, the medium was aspirated and replenished with
RPMI/B-27 minus insulin and replaced every 2 days. From day 7,
differentiated cells were maintained in RPMI/B-27 containing in-
sulin and replenished in every 3 days. Spontaneous beating pheno-
type should occur from day 7 to 9 onward.
RNA-Seq Analysis
See Supplemental Information.
ACCESSION NUMBERS
Analyzed data are provided in Supplemental Tables. Genome-wide
datasets are deposited at the GEO under accession number GEO:
GSE121877 and GSE99202.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, three tables, and one video and can be
found with this article online at https://doi.org/10.1016/j.stemcr.
2018.10.013.
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